References
- Abuse S Mental Health Services Administration (SAMHSA), 2014. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14–4863. Substance Abuse and Mental Health Services Administration, Rockville, MD. 2017.
- Crime UNOoDa. World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). 2019.
- Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014;311:1889–900.
- Sofuoglu M, DeVito EE, Carroll KM. Pharmacological and behavioral treatment of opioid use disorder. Psychiatric Res. 2018;1:4–15. doi:https://doi.org/10.1176/appi.prcp.20180006.
- Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol. 2014;7:363–74. doi:https://doi.org/10.1586/17512433.2014.909283.
- Kohno M, Dennis LE, McCready H, Schwartz DL, Hoffman WF, Korthuis PT. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend. 2018;192:186–92. doi:https://doi.org/10.1016/j.drugalcdep.2018.07.045.
- Li Q, Li W, Wang H, Wang Y, Zhang Y, Zhu J, Zheng Y, Zhang D, Wang L, Li Y, et al. Predicting subsequent relapse by drug‐related cue‐induced brain activation in heroin addiction: an event‐related functional magnetic resonance imaging study. Addict Biol. 2015;20:968–78.
- Strong DR, Leventhal AM, Evatt DP, Haber S, Greenberg BD, Abrams D, Niaura R. Positive reactions to tobacco predict relapse after cessation. J Abnorm Psychol. 2011;120:999.
- Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal AM, Shotaw S, Heinzerling K, London ED, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015;40:2347.
- Marks KR, Lile JA, Stoops WW, Glaser PE, Hays LR, Rush CR. Separate and combined effects of naltrexone and extended-release alprazolam on the reinforcing, subject-rated, and cardiovascular effects of methamphetamine. J Clin Psychopharmacol. 2016;36:213. doi:https://doi.org/10.1097/JCP.0000000000000488.
- Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology. 2008;33:1856. doi:https://doi.org/10.1038/sj.npp.1301572.
- Coffin PO, Santos GM, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki SL. Extended‐release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo‐controlled trial. Addiction. 2018;113:268–78.
- Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS & Neurolog Disorders-Drug Tar. 2010;9:13–22.
- Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, Lim AC, Gillis A, Miotto K. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45:124–40.
- van der Stel J. Focus: personalized medicine: precision in addiction care: does it make a difference? Yale J Biol Med. 2015;88:415.
- Heinzerling KG, Swanson AN, Hall TM, Yi Y, Wu Y, Shoptaw SJ. Randomized, placebo‐controlled trial of bupropion in methamphetamine‐dependent participants with less than daily methamphetamine use. Addiction. 2014;109:1878–86. doi:https://doi.org/10.1111/add.12636.
- Chamorro AJ, Marcos M, Mirón‐Canelo JA, Pastor I, González‐Sarmiento R, Laso FJ. Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis. Addict Biol. 2012;17:505–12. doi:https://doi.org/10.1111/j.1369-1600.2012.00442.x.
- Jonas DE, Amick HR, Feltner C, Wines R, Shanahan E, Rowe CJ, Garbutt JC. Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. Pharmacogenomics. 2014;15:1687–700.
- Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135–68. doi:https://doi.org/10.1146/annurev-psych-113011-143750.
- Nowrangi MA, Lyketsos C, Rao V, Munro CA. Systematic review of neuroimaging correlates of executive functioning: converging evidence from different clinical populations. J Neuropsychiatry Clin Neurosci. 2014;26:114–25. doi:https://doi.org/10.1176/appi.neuropsych.12070176.
- Ray LA, Green R, Roche DJ, Bujarski S, Hartwell EE, Lim AC, Rohrbaugh T, Ghahremani D, Hutchison K, Miotto K. Pharmacogenetic effects of Naltrexone in individuals of East Asian descent: human laboratory findings from a randomized trial. Alcohol Clin Exp Res. 2018;42:613–23.
- Courtney KE, Ghahremani DG, Ray LA. The effects of pharmacological opioid blockade on neural measures of drug cue-reactivity in humans. Neuropsychopharmacology. 2016;41:2872. doi:https://doi.org/10.1038/npp.2016.99.
- Lim AC, Ghahremani DG, Grodin EN, Green R, Bujarski S, Hartwell EE, Courtney KE, Hutchison K, Miotto K, Ray LA. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. Drug and alcohol dependence. 2019;200:181–90. doi:https://doi.org/10.1016/j.drugalcdep.2019.02.028.
- Becker A, Kirsch M, Gerchen MF, Kiefer F, Kirsch P. Striatal activation and frontostriatal connectivity during non‐drug reward anticipation in alcohol dependence. Addict Biol. 2017;22:833–43. doi:https://doi.org/10.1111/adb.2017.22.issue-3.
- Weafer J, Gorka SM, Hedeker D, Dzemidzic M, Kareken DA, Phan KL, de Wit H. Associations between behavioral and neural correlates of inhibitory control and amphetamine reward sensitivity. Neuropsychopharmacology. 2017;42:1905.
- Tabibnia G, Monterosso JR, Baicy K, Aron AR, Poldrack RA, Chakrapani S, Lee B, London ED. Different forms of self-control share a neurocognitive substrate. J Neurosci. 2011;31:4805–10.
- Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system: technical manual. San Antonio (TX): Psychological Corporation; 2001.
- Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan Executive Function System: an update. J Int Neuropsychol Soc. 2004;10:301–03. doi:https://doi.org/10.1017/S1355617704102191.
- Karr JE, Hofer SM, Iverson GL, Garcia-Barrera MA. Examining the latent structure of the Delis–Kaplan executive function system. Arch Clin Neuropsychol. 2018;34:381–94. doi:https://doi.org/10.1093/arclin/acy043.
- Dean AC, Groman SM, Morales AM, London ED. An valuation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology. 2013;38:259. doi:https://doi.org/10.1038/npp.2012.179.
- Mitchell M, Miller LS. Prediction of functional status in older adults: the ecological validity of four Delis–Kaplan executive function system tests. J Clin Exp Neuropsychol. 2008;30:683–90. doi:https://doi.org/10.1080/13803390701679893.
- Homack S, Lee D, Riccio CA. Test review: Delis-Kaplan executive function system. J Clin Exp Neuropsychol. 2005;27:599–609. doi:https://doi.org/10.1080/13803390490918444.
- Parmenter BA, Zivadinov R, Kerenyi L, Gavett R, Weinstock-Guttman B, Dwyer MG, Garg N, Munschauer F, Benedict RHB. Validity of the Wisconsin card sorting and Delis–Kaplan executive function system (DKEFS) sorting tests in multiple sclerosis. J Clin Exp Neuropsychol. 2007;29:215–23.
- Heled E, Hoofien D, Margalit D, Natovich R, Agranov E. The Delis–Kaplan executive function system sorting test as an evaluative tool for executive functions after severe traumatic brain injury: A comparative study. J Clin Exp Neuropsychol. 2012;34:151–59. doi:https://doi.org/10.1080/13803395.2011.625351.
- McDonald CR, Delis DC, Norman MA, Wetter SR, Tecoma ES, Iragui VJ. Response inhibition and set shifting in patients with frontal lobe epilepsy or temporal lobe epilepsy. Epilepsy & Behavior. 2005;7:438–46. doi:https://doi.org/10.1016/j.yebeh.2005.05.005.
- Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17:275–97.
- Potvin S, Pelletier J, Grot S, Hebert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav. 2018;80:154–60. doi:https://doi.org/10.1016/j.addbeh.2018.01.021.
- Dean AC, Morales AM, Hellemann G, London ED. Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. Neuropsychopharmacology. 2018;43:1745. doi:https://doi.org/10.1038/s41386-018-0065-1.
- Ersche KD, Turton AJ, Chamberlain SR, Müller U, Bullmore ET, Robbins TW. Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry. 2012;169:926–36. doi:https://doi.org/10.1176/appi.ajp.2012.11091421.
- Canli T, Cook RG, Miczek KA. Opiate antagonists enhance the working memory of rats in the radial maze. Pharmacology Biochem Beha. 1990;36:521–25. doi:https://doi.org/10.1016/0091-3057(90)90250-L.
- Rodefer JS, Nguyen TN. Naltrexone reverses age-induced cognitive deficits in rats. Neurobiol Aging. 2008;29:309–13. doi:https://doi.org/10.1016/j.neurobiolaging.2006.10.005.
- Cobb BL, Jauchem JR, Adair ER. Radial arm maze performance of rats following repeated low level microwave radiation exposure. Bioelectromagnetics. 2004;25:49–57. doi:https://doi.org/10.1002/()1521-186X.
- Lai H, Horita A, Guy AW. Microwave irradiation affects radial‐arm maze performance in the rat. Bioelectromagnetics. 1994;15:95–104. doi:https://doi.org/10.1002/()1521-186X.
- Oberlin BG, Bristow RE, Heighton ME, Grahame NJ. Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. Alcohol Clin Exp Res. 2010;34:1363–75.
- Messinis L, Lyros E, Andrian V, Katsakiori P, Panagis G, Georgiou V, Papathanasopoulos P. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy. Hum Psychopharmacol. 2009;24:524–31.
- Ralevski E, Balachandra K, Gueorguieva R, Limoncelli D, Petrakis I. Effects of naltrexone on cognition in a treatment study of patients with schizophrenia and comorbid alcohol dependence. J Dual Diagn. 2006;2:53–69. doi:https://doi.org/10.1300/J374v02n04_05.
- Pomara N, Roberts R, Rhiew HB, Stanley M, Gershon S. Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer’s disease. Neurobiol Aging. 1985;6:233–36. doi:https://doi.org/10.1016/0197-4580(85)90055-7.
- Hatsukami DK, Mitchell JE, Morley JE, Morgan SF, Levine AS. Effect of naltrexone on mood and cognitive functioning among overweight men. Biol Psychiatry. 1986;21:293–300. doi:https://doi.org/10.1016/0006-3223(86)90050-8.
- First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV-TR Axis I disorders: patient edition: biometrics research department. New York (NY): Columbia University; 2005.
- Pearson N. Advanced clinical solutions for WAIS-IV and WMS-IV: administration and scoring manual. San Antonio (TX): The Psychological Corporation. 2009.
- Inagaki TK, Ray LA, Irwin MR, Way BM, Eisenberger NI. Opioids and social bonding: naltrexone reduces feelings of social connection. Soc Cogn Affect Neurosci. 2016;11:728–35. doi:https://doi.org/10.1093/scan/nsw006.
- Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li S-H, Elkashef A, Chiang N, Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31:1537–44.
- Newton TF, Reid MS, De La Garza R, Mahoney III JJ, Abad A, Condos R, Palamar J, Halkitis PN, Mojisak J, Anderson A, et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2008;11:1037–45.
- Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O’Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227:177–92. doi:https://doi.org/10.1007/s00213-012-2954-z.
- Moallem NR, Courtney KE, Ray LA. The relationship between impulsivity and methamphetamine use severity in a community sample. Drug Alcohol Depend. 2018;187:1–7. doi:https://doi.org/10.1016/j.drugalcdep.2018.01.034.
- Lim AC, Cservenka A, Ray LA. Effects of alcohol dependence severity on neural correlates of delay discounting. Alcohol and Alcoholism. 2017;52:506–15. doi:https://doi.org/10.1093/alcalc/agx015.
- Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, Rawson R, London ED. Withdrawal symptoms in abstinent methamphetamine‐dependent subjects. Addiction. 2010;105:1809–18.
- Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42:49–54. doi:https://doi.org/10.1016/0376-8716(96)01263-X.
- Bujarski S, Hutchison KE, Prause N, Ray LA. Functional significance of subjective response to alcohol across levels of alcohol exposure. Addict Biol. 2017;22:235–45. doi:https://doi.org/10.1111/adb.2017.22.issue-1.
- Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington (VA): American Psychiatric Pub; 2013.
- Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, et al. Naltrexone ameliorates functional network abnormalities in alcohol‐dependent individuals. Addict Biol. 2018;23:425–36.
- Elton A, Dove S, Spencer CN, Robinson DL, Boettiger CA. Naltrexone acutely enhances connectivity between the ventromedial prefrontal cortex and a left frontoparietal network. Alcohol Clin Exp Res. 2019;43:965–78. doi:https://doi.org/10.1111/acer.2019.43.issue-5.
- Yu S, Zhu L, Shen Q, Bai X, Di X. Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. In: Behavioural Neurology. 2015;2015:103969.
- Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding Y-S, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377–82.
- Vonmoos M, Hulka LM, Preller KH, Jenni D, Baumgartner MR, Stohler R, Bolla KI, Quednow BB. Cognitive dysfunctions in recreational and dependent cocaine users: role of attention-deficit hyperactivity disorder, craving and early age at onset. Br J Psychiatry. 2013;203:35–43.
- Bernardin F, Maheut-Bosser A, Paille F. Cognitive impairments in alcohol-dependent subjects. Frontiers in Psychiatry. 2014;5:78. doi:https://doi.org/10.3389/fpsyt.2014.00078.
- Dean AC, London ED, Sugar CA, Kitchen CM, Swanson AN, Heinzerling KG, Kalechstein AD, Shoptaw S. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009;105:48–55.
- Dean AC, Sevak RJ, Monterosso JR, Hellemann G, Sugar CA, London ED. Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans. J Stud Alcohol Drugs. 2011;72:943–53. doi:https://doi.org/10.15288/jsad.2011.72.943.
- Hester R, Lee N, Pennay A, Nielsen S, Ferris J. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence. Exp Clin Psychopharmacol. 2010;18:489.
- Domínguez-Salas S, Díaz-Batanero C, Lozano-Rojas OM, Verdejo-García A. Impact of general cognition and executive function deficits on addiction treatment outcomes: systematic review and discussion of neurocognitive pathways. Neurosci Biobehav Rev. 2016;71:772–801.
- Rezapour T, DeVito EE, Sofuoglu M, Ekhtiari H. Perspectives on neurocognitive rehabilitation as an adjunct treatment for addictive disorders: from cognitive improvement to relapse prevention. Prog Brain Res. 2016;224, Elsevier:345–69.
- Ekhtiari H, Rezapour T, Aupperle RL, Paulus MP. Neuroscience-informed psychoeducation for addiction medicine: A neurocognitive perspective. Prog Brain Res. 2017;235, Elsevier:239–64.
- Martel M, Nikolas M, Nigg JT. Executive function in adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:1437–44.
- Green R, Grodin E, Lim AC, Venegas A, Bujarski S, Krull J, Ray LA. The interplay between subjective response to alcohol, craving, and alcohol self‐administration in the human laboratory. Alcohol Clin Exp Res. 2019;43:907–15.
- Huckans M, Fuller BE, Chalker AL, Adams M, Loftis JM. Plasma inflammatory factors are associated with anxiety, depression, and cognitive problems in adults with and without methamphetamine dependence: an exploratory protein array study. Frontiers in Psychiatry. 2015;6:178.
- Ruan X, Zhong N, Yang Z, Fan X, Zhuang W, Du J, Jiang H, Zhao M. Gray matter volume showed dynamic alterations in methamphetamine users at 6 and 12 months abstinence: A longitudinal voxel-based morphometry study. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:350–55.